Abstract
Chronic bacterial infection is one of the key challenges in caring for patients with cystic fibrosis (CF). Effective infection control requires appropriate administration of antibiotics. Inhaled antibiotics play a pivotal role in CF management. Pathogens in CF patients target the lumen of the lung, a cavity that is difficult to access via the oral or intravenous route. Aerosolized antibiotics deliver effective local drug concentrations to the infection site and decrease the risk of systemic side effects associated with oral or intravenous antibiotics. However, effective aerosolized antibiotic therapy must ensure reliable drug delivery to the lower respiratory tract with a beneficial pharmacodynamic profile and high potency.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.